You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The immunoassay can be used to monitor cancer cell remnants in a patient's body and help determine which patients need less invasive treatment.
The company said the test can be used to evaluate effective antibody levels after SARS-CoV-2 infection or vaccination, as well as to assess adaptive immunity.
The firm's assay leverages reverse transcriptase quantitative PCR to amplify two separate regions of the HIV-1 genome to monitor HIV-infected patients.
The test leverages ELISA technology and uses non-pathogenic viral proteins, enabling its use in common lab settings either manually or automatically.
The panel, which includes three immunoassays, identifies the infection stage of the Epstein-Barr virus from a blood sample.
The firm's test reader can be attached to any smartphone to take images of the test results and send them to be interpreted by artificial intelligence.
The automated sample-to-answer platform allows for a variety of assay types to be run simultaneously, such as molecular, immunochemistry, and cytometry tests.
The company said the test detects four SARS-CoV-2 variants and two biologically significant mutations, all of which are now prevalent globally.
The test is fully automated from sample to result interpretation and requires one whole-blood sample tube with no manual sample preparation necessary.
The firm said it will begin running its urine-based test immediately in its clinical laboratory in Munich and make it available throughout Europe.